SEATTLE, May 12 /PRNewswire-FirstCall/ -- Trubion
Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced the acceptance
of two Phase 1 data presentations on SBI-087 (PF-05230895) at the
2010 annual congress of the European League Against Rheumatism
(EULAR) in Rome, Italy.
Presentations will include promising data from a Phase 1 study of
SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase
1 study of SBI-087 for the treatment of systemic lupus
erythematosus (SLE). Copies of both abstracts are available at
http://www.eular.org. SBI-087 is Trubion's next-generation
CD20-directed small modular immunopharmaceutical (SMIP™) product
candidate and is being developed in collaboration with Pfizer.
(Logo:
http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO)
Abstract OP0053:
Subcutaneous (SC) administration of SBI-087 provides potent B-cell
depletion in subjects with controlled RA
|
|
Oral
Presentation
|
|
June 17, 2010; 10:30
a.m.–Noon
|
|
Room 8 B
|
|
Roy
Fleischmann
|
|
|
The Phase 1 trial was designed to evaluate the safety,
tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of
ascending single doses of SBI-087 in patients with controlled RA.
At the time of the abstract submission, 60 patients enrolled in the
open-label Phase 1 trial had received intravenous doses of SBI-087
ranging from 0.15 to 2 mg/kg or subcutaneous doses of 50, 100, 200
and 300 mg. All of the patients studied had well-controlled RA.
Data demonstrate that SBI-087, given as a single subcutaneous
dose with a day-of-treatment oral steroid regimen, is generally
well-tolerated and induces potent B-cell depletion. The most
frequently reported adverse events were upper respiratory
infection, headache, diarrhea, chills, fever, fatigue and bruising
at the injection site. SBI-087 administered at subcutaneous doses
of at least 100 mg depleted peripheral blood B-cell levels to less
than 5 cells/uL for at least 12 weeks. Trubion's collaboration
partner, Pfizer, initiated a Phase 2 study of SBI-087 for RA in
January to evaluate safety and efficacy of SBI-087. The 200 mg
subcutaneous dose was selected to be further investigated as part
of this trial.
Abstract SAT0188:
B-cell depletion in subjects with controlled systemic lupus
erythematosus (SLE) after intravenous or subcutaneous
administration of SBI-087
|
|
Poster
Presentation
|
|
June 19, 2010;
10:15–Noon
|
|
Fiera Roma – Poster
Areas in Halls 5 & 6
|
|
|
At the time of abstract submission, data was available for 18
patients enrolled in an open-label Phase 1 study of SBI-087 for
SLE. Patients received intravenous doses of 0.5 mg/kg or
subcutaneous doses of 25 mg or 75 mg of SBI-087. All patients had
well-controlled SLE.
Preliminary data demonstrate that SBI-087 was generally
well-tolerated by patients with well-controlled lupus when
administered as a single subcutaneous dose with a day-of-treatment
oral steroid regimen. Adverse events included chills, extreme
fatigue, upper respiratory tract infection and muscle spasms.
Subcutaneous doses of 75 mg of SBI-087 depleted peripheral blood
B-cell levels in all subjects to below 20 cells/uL. Five of six
subjects in this cohort had B-cell levels below 5 cells/uL by week
two. By week 10, B-cell levels increased to above 20 cells/uL in
four of six subjects. The Phase 1 trial is ongoing and is designed
to evaluate the safety, tolerability, pharmacokinetics (PK) and
pharmacodynamics (PD) of ascending single doses of SBI-087 in
patients with controlled SLE.
"Data to be presented at EULAR reinforce the need for
differentiated treatments for RA and SLE," said Scott Stromatt, M.D., chief medical officer of
Trubion. "We look forward to continued evaluation of our second
generation CD20 compound and further defining its role in the
treatment of RA and SLE."
About Trubion
Trubion is a biopharmaceutical company that is creating a
pipeline of novel protein therapeutic product candidates to treat
autoimmune and inflammatory diseases and cancer. The Company's
mission is to develop a variety of first-in-class and best-in-class
product candidates, customized for optimal safety, efficacy and
convenience that it believes may offer improved patient
experiences. Trubion's current product candidates are novel
single-chain protein, or SMIP, therapeutics, and are designed using
its custom drug assembly technology. Trubion's product pipeline
includes CD20-directed SMIP therapeutics such as TRU-015 and
SBI-087 for autoimmune and inflammatory diseases, developed under
the Company's Pfizer collaboration. Trubion's product pipeline also
includes TRU-016, a novel CD37-targeted therapy for the treatment
of B-cell malignancies developed under the Company's Facet
collaboration. In addition to Trubion's current clinical stage
product pipeline, the Company is also developing its multi-specific
SCORPION technology, both for targeting cell-surface molecules as
well as simultaneously neutralizing soluble ligands. More
information is available in the investors section of Trubion's
website: http://investors.trubion.com/index.cfm.
Forward-Looking Statements
Certain statements in this release may constitute
"forward-looking statements" within the meaning of Section 21E of
the Securities Exchange Act of 1934 and Section 27A of the
Securities Act of 1933. These statements include, but are not
limited to, those related to the Company's future clinical
development programs, the timing and availability of data resulting
from these programs and the intentions of the Company's
collaboration partners, including Facet and its parent corporation,
Abbott, the Company's future regulatory filings and the timing and
outcome thereof, the Company's receipt of future milestone payments
under existing collaborations, the Company's projected cash
requirements for future periods and other projected financial
results. These statements are based on current expectations and
assumptions regarding future events and business performance and
involve certain risks and uncertainties that could cause actual
results to differ materially. These risks include, but are not
limited to, risks associated with the Company's Pfizer
collaboration, including Pfizer's control over development
timelines and over decisions regarding the advancement of some of
the Company's clinical development programs, risks associated with
the Company's Facet collaboration, including Facet's and Abbott's
control over development timelines and over decisions regarding the
advancement of some of the Company's clinical development programs,
the risks that the Company is unable to advance its clinical
development programs and regulatory applications and action at the
rate it expects, the risks that data resulting from our clinical
development programs are unfavorable or uncertain, the risk that we
do not achieve the milestones we expect to generate milestone
payments under our collaboration agreements or otherwise do not
receive these milestone payments for any reason, the risk that our
projected cash requirements exceed our expectations and such other
risks as identified in the Company's report on Form 10-Q for the
quarter ended March 31, 2010, and
from time to time in other reports filed by Trubion with the U.S.
Securities and Exchange Commission. These reports are available on
the Investors page of the Company's corporate website at
http://www.trubion.com. Trubion undertakes no duty to update any
forward-looking statement to conform the statement to actual
results or changes in the Company's expectations.
TRBN-087RA
Contact:
|
|
Jim DeNike
|
|
Senior Director,
Corporate Communications
|
|
Trubion
Pharmaceuticals, Inc.
|
|
(206)
838-0500
|
|
jdenike@trubion.com
|
|
http://www.trubion.com
|
|
|
|
Waggener Edstrom
Worldwide Healthcare
|
|
Amy Petty
|
|
Account
Manager
|
|
(617)
576-5788
|
|
amyp@waggeneredstrom.com
|
|
|
SOURCE Trubion Pharmaceuticals, Inc.